Go-ahead for LCT
Tuesday, 21 October, 2008
Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.
NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.
A parallel Phase I/IIa trial commenced in Russia in 2007.
According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.
DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
